°òª÷·|»PÂø»x | §ÜÀù¸ê°T | ·|­ûµù¥U | ¯f¤Í¶é¦a | ÂåÀøÅU°Ý | ³Ì·s¤åÄm | ¬ÛÃöºô¯¸ | ½u¤W®½´Ú | ³Ì·s®ø®§


¶i®i©ÊÀYÀV³¡¸~½F¯f±wÀH¾÷±µ¨ü¤Æ¾Ç©ñ®gÀøªk©Î¦X¨ÖTirapazamine¥H[18F]-Misonidazole¥¿¤l³y¼vÅã¥Ü¯Ê®ñªº¹w«á­«­n©Ê¡G TROG²Ä98.02¸¹Á{§É¸ÕÅç¤l¸s²Õ¤ÀªR
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography-Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine:
A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02

J Clin Oncol, 2006, Vol. 24: 2098-104
By Danny Rischin, Rodney J. Hicks, Richard Fisher, et. al

ĶªÌ¡G¾H¥ò¤¯

¤@¡B ¬ã¨s¥Øªº
°w¹ï¿©±w²ÄIII©Î²ÄIV´ÁÀYÀV³¡Å쪬²Ó­MÀù±wªÌ¡A¤©¥HÀH¾÷¤À°t¦Ü2²Õ¡GTPZ/CIS²Õ¬°©ñ®g½uªvÀø¡]7¶gµ¹¤©35¦¸©ñ®gªvÀø¡AÁ`¾¯¶q70 Gy¡^¦X¨Ö²Ä1¡B²Ä4¡B²Ä7¶gµ¹¤©tirapazamine¡Ïcisplatin¥H¤Î²Ä2¡B²Ä3¶g³æ¿Wµ¹¤©tirapazamine¡F¥t¥~¤Æ¾Ç±j¤ÆªvÀø²Õ(chemoboost)¬°©ñ®g½uªvÀø¦X¨Ö²Ä6¡B²Ä7¶gµ¹¤©cisplatin¡ÏÀR¯ßª`®g«¬fluorouracil¡Cµû¦ô¸~½F¯Ê®ñ(tumor hypoxia)¡BªvÀø³B¤è(treatment regimen)¡C¥H¤Î§½³¡ªvÀø¥¢±Ñ(locoregional failure)¤§¶¡ªº¬ÛÃö©Ê¡C

¤G¡B ¬ã¨s¹ï¶H»P¤èªk
Á`¦@¦³45¦W¯f±w¶i¤J³o­Ó¤j«¬ÀH¾÷¸ÕÅ礤¯Ê®ñÄá¼v(hypoxic imaging)ªº¤l¬ã¨s¡C¦bªvÀø«e»PªvÀø´Á¶¡¡A¶i¦æ[18F]-fluoromisonidazole¥¿¤lÄá¼v(FMISO-PET)¡]¦bµ¹¤©©ñ®g½uª«½è2¤p®É«á·Ó¬ÛÄá¼v¡^¡A¨Ã¥H©w©Êµ¹¤À¼Ð·Ç(qualitative scoring)´ú©w­ìµo¸~½F»P²O¤Úµ²ªº§l¦¬¤Î¯Ê®ñ»P§_±¡§Î¡C

¤T¡B ¬ã¨sµ²ªG
¦b45¦W¯f±w¤¤¡ATPZ/CIS²Õ¦³22¦W¯f±w¡A¤Æ¾Ç±j¤ÆªvÀø²Õ¦³23¦W¯f±w¡CÁ`¦@¦³32¦W¯f±w¡]71%¡^¦b­ìµo¸~½F³¡¦ì©Î/¤Î²O¤Úµ²°»´ú¨ì¯Ê®ñ°T¸¹¡C
±µ¨ü¤Æ¾Ç±j¤ÆªvÀø²Õ¡A¨S¦³¯Ê®ñ°T¸¹ªº10¦W¯f±w¤¤¡A¦³1¦W§½³¡ªvÀø¥¢±Ñ¡F¦Ó¦³¯Ê®ñ°T¸¹ªº13¦W¯f±w¤¤¡A¦³8¦W§½³¡ªvÀø¥¢±Ñ¡F²Î­pµ²ªGÅã¥Ü¡A¦³¯Ê®ñ±¡§Î®É§½³¡ªvÀø¥¢±Ñªº¾÷·|ÅãµÛ¸û°ª¡]¨Ï¥Îºë½T«ü¼Æ¨t¦Cªk(exact log-rank)¡Ap­È¡×.038¡A¦M®`¤ñ¡×7.1¡^¡C¬Û¸û¤§¤U¡ATPZ/CIS²Õ¤¤¡A¦³¯Ê®ñ°T¸¹ªº19¦W¯f±w¥u¦³1¦W§½³¡ªvÀø¥¢±Ñ¡C¦]¦¹±µ¨ü¤Æ¾Ç±j¤ÆªvÀø²Õµo¥Í§½³¡ªvÀø¥¢±Ñªº¾÷·|¦³ÅãµÛ¸û°ª¡Ap­È¡×.001¡A¦M®`¤ñ¡×15¡C
­Y¥u¤ñ¸û­ìµo³¡¦ì¡ATPZ/CIS²Õ¤¤¦³¯Ê®ñ¯f¨_ªº8¦W¯f±w¨S¦³¤H§½³¡ªvÀø¥¢±Ñ¡A¦Ó¤Æ¾Ç±j¤ÆªvÀø²Õªº9¦W¯f±w¤¤«h¦³6¦W§½³¡ªvÀø¥¢±Ñ¡CTPZ/CIS²Õ§½³¡ªvÀø¥¢±Ñªº¾÷·|¸û¤p¡Ap­È¡×.011¡A¦M®`¤ñ¡×0¡C

¥|¡B µ²½×
­Y¯f±w±µ¨üªºÀøµ{¬O¤£§ttirapazamineªº¤Æ¾Ç©ñ®g¦X¨ÖÀøªk¡A¦bFMISO-PET³y¼v¦³¯Ê®ñ±¡§ÎªÌ¦³¸û°ªªº¾÷·|µo¥Í§½³¡ªvÀø¥¢±Ñ¡C
¥»¶µÁ{§É¸ÕÅ窺µ²ªG¦P®É¤]¬O­º¦¸Á{§ÉªºÃÒ¾Ú¡A¤ä«ù¥ý«e¹êÅç«ÇùØ©ÒÆ[¹î¨ìªº±¡§Î¡Gtirapazamine·|¯S©w¦a§@¥Î¦b¯Ê®ñ©Êªº¸~½F²Ó­M¤W¡C

 

 
 
µn¿ý®É¶¡¡G95¦~9¤ë1¤é